JP7372259B2 - 結晶トラニラスト塩およびこれらの医薬的な使用 - Google Patents

結晶トラニラスト塩およびこれらの医薬的な使用 Download PDF

Info

Publication number
JP7372259B2
JP7372259B2 JP2020555115A JP2020555115A JP7372259B2 JP 7372259 B2 JP7372259 B2 JP 7372259B2 JP 2020555115 A JP2020555115 A JP 2020555115A JP 2020555115 A JP2020555115 A JP 2020555115A JP 7372259 B2 JP7372259 B2 JP 7372259B2
Authority
JP
Japan
Prior art keywords
tranilast
salt
crystalline
peaks
infrared spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533080A5 (cg-RX-API-DMAC7.html
JP2021533080A (ja
Inventor
ホランド、ジョアン
フランプトン、クリストファー
Original Assignee
ナフォーミックス テクノロジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナフォーミックス テクノロジーズ リミテッド filed Critical ナフォーミックス テクノロジーズ リミテッド
Publication of JP2021533080A publication Critical patent/JP2021533080A/ja
Publication of JP2021533080A5 publication Critical patent/JP2021533080A5/ja
Application granted granted Critical
Publication of JP7372259B2 publication Critical patent/JP7372259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/68—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020555115A 2018-08-14 2019-08-14 結晶トラニラスト塩およびこれらの医薬的な使用 Active JP7372259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718563P 2018-08-14 2018-08-14
US62/718,563 2018-08-14
PCT/EP2019/071881 WO2020035546A1 (en) 2018-08-14 2019-08-14 Crystalline tranilast salts and their pharmaceutical use

Publications (3)

Publication Number Publication Date
JP2021533080A JP2021533080A (ja) 2021-12-02
JP2021533080A5 JP2021533080A5 (cg-RX-API-DMAC7.html) 2022-10-28
JP7372259B2 true JP7372259B2 (ja) 2023-10-31

Family

ID=67997566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555115A Active JP7372259B2 (ja) 2018-08-14 2019-08-14 結晶トラニラスト塩およびこれらの医薬的な使用

Country Status (5)

Country Link
US (2) US11078155B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837238B1 (cg-RX-API-DMAC7.html)
JP (1) JP7372259B2 (cg-RX-API-DMAC7.html)
CN (1) CN112236413A (cg-RX-API-DMAC7.html)
WO (1) WO2020035546A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078155B2 (en) * 2018-08-14 2021-08-03 Nuformix Technologies Limited Crystalline tranilast salts and their pharmaceutical use
US20230146308A1 (en) * 2020-03-19 2023-05-11 Softhale Nv Method for the treatment nlrp3-associated diseases
AU2022443590A1 (en) 2022-02-28 2024-10-17 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ,インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2005247819A (ja) 2003-09-30 2005-09-15 Rohto Pharmaceut Co Ltd 透明包装体入りトラニラスト含有医薬製剤
JP2006306765A (ja) 2005-04-27 2006-11-09 Nippon Tenganyaku Kenkyusho:Kk トラニラスト水性点眼液
WO2007046544A1 (ja) 2005-10-21 2007-04-26 Medrx Co., Ltd. カルボキシル基を有する肥満細胞脱顆粒抑制剤と有機アミンとの塩を含有する外用剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5848545B2 (ja) * 1974-04-18 1983-10-28 キツセイヤクヒンコウギヨウ カブシキガイシヤ シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ
US4587356A (en) * 1981-09-01 1986-05-06 Kissei Pharmaceutical Co., Ltd. Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives
EP0189861A3 (en) * 1985-01-26 1988-02-17 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
ES8606846A1 (es) * 1985-07-11 1986-05-16 Uriach & Cia Sa J Procedimiento de obtencion del acido 2-((3-3,4-dimetoxifenil-1-oxo-2-propenil)amino)benzoico
JPH07116029B2 (ja) 1989-04-04 1995-12-13 キッセイ薬品工業株式会社 トラニラスト水溶液製剤
JP2001187728A (ja) * 1999-12-28 2001-07-10 Lion Corp 眼科用組成物
WO2010071865A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
CN104379130B (zh) 2012-03-30 2018-01-02 诺弗米克斯有限公司 曲尼司特组合物和共结晶体
KR101878370B1 (ko) 2016-12-30 2018-07-13 한국과학기술원 진동 감쇠 장치
US11078155B2 (en) * 2018-08-14 2021-08-03 Nuformix Technologies Limited Crystalline tranilast salts and their pharmaceutical use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ,インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2005247819A (ja) 2003-09-30 2005-09-15 Rohto Pharmaceut Co Ltd 透明包装体入りトラニラスト含有医薬製剤
JP2006306765A (ja) 2005-04-27 2006-11-09 Nippon Tenganyaku Kenkyusho:Kk トラニラスト水性点眼液
WO2007046544A1 (ja) 2005-10-21 2007-04-26 Medrx Co., Ltd. カルボキシル基を有する肥満細胞脱顆粒抑制剤と有機アミンとの塩を含有する外用剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"新医薬品の規格及び試験方法の設定について",医薬審発第568号,2001年05月01日
Crystal growth and design,2013年,13(8),p.3546-3553
Journal of Pharmaceutical Sciences,1977年,Vol.66, No.1,p.1-19
小野誠,塩選択の現状分析,薬剤学,2013年,73(3),p.176-182
山野光久,医薬品のプロセス研究における結晶多形現象への取り組み,有機合成化学協会誌,2007年,65(9),p.907-913
川口洋子ら,医薬品と結晶多形,生活工学研究,2002年,Vol.4, No.2,p.310-317
高田則幸,創薬段階における原薬Formスクリーニングと選択,PHARM STAGE,Vol.6, No.10,2007年01月15日,p.20-25

Also Published As

Publication number Publication date
CN112236413A (zh) 2021-01-15
EP3837238B1 (en) 2024-06-12
EP3837238A1 (en) 2021-06-23
US20210155577A1 (en) 2021-05-27
WO2020035546A1 (en) 2020-02-20
JP2021533080A (ja) 2021-12-02
US12084399B2 (en) 2024-09-10
EP3837238C0 (en) 2024-06-12
US11078155B2 (en) 2021-08-03
US20210332003A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US10150729B2 (en) Tranilast compositions and cocrystals
US12084399B2 (en) Crystalline tranilast salts and their pharmaceutical use
TWI540131B (zh) 阿瑞吡坦(aprepitant)l-脯胺酸組成物及共晶體
JP7453475B2 (ja) オラパリブシュウ酸共結晶及びその医薬的使用
JP7597771B2 (ja) 治療のためのベンズアミド共結晶
WO2023222122A1 (en) Solid forms of a compound for treating or preventing hyperuricemia or gout
HK40049105A (en) Crystalline tranilast salts and their pharmaceutical use
HK40049105B (en) Crystalline tranilast salts and their pharmaceutical use
AU2023218670A1 (en) Crystal form of cyclohexenone compound
HK1206619B (en) Tranilast compositions and cocrystals

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221014

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231019

R150 Certificate of patent or registration of utility model

Ref document number: 7372259

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150